Miyauchi, Akimitsu
Hamaya, Etsuro
Nishi, Kiyoshi
Tolman, Cae
Shimauchi, Junichiro
Funding for this research was provided by:
Amgen K.K.
Article History
Received: 4 November 2021
Accepted: 1 April 2022
First Online: 31 May 2022
Declarations
:
: A. Miyauchi received consulting fees from Amgen K.K., and Teijin Pharma. E. Hamaya, K. Nishi, and J. Shimauchi are employees of Amgen K.K., and E. Hamaya owns stock in Amgen Inc. C. Tolman is an employee of Amgen K.K. and owns stock in Amgen Inc.
: The trial was conducted according to the Declaration of Helsinki: ethical principles for medical research involving human subjects, and the study protocol was approved by the ethics committee or institutional review board at each study center. Informed consent was obtained from all individual participants included in the study.